Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-12357673-B2
Application number	US-202117561606-A
Country	US
Kind code	B2
Filing date	Dec 23, 2021
Priority date	Jan 10, 2018
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

First claim

The invention claimed is:

1. A method of treating cancer in a mammalian subject in need thereof, comprising:
administering to the mammalian subject an effective amount of a composition comprising a polypeptide comprising albumin protein linked to a FMS-like tyrosine kinase 3 ligand (Flt3L) protein comprising a sequence having at least 80% identity to SEQ ID NO: 1, to thereby treat the cancer in the mammalian subject.

2. The method of claim 1 , wherein the method further comprises administering to the mammalian subject an effective amount of at least one additional chemotherapeutic agent.

3. The method of claim 1 , wherein the method further comprises administering to the mammalian subject an effective amount of an immunotherapeutic agent.

4. The method of claim 3 , wherein the immunotherapeutic agent is a PD-1 inhibitor.

5. The method of claim 1 , wherein the method further comprises administering to the mammalian subject an effective amount of radiation therapy.

6. The method of claim 5 , wherein the radiation therapy is focused radiation therapy.

7. The method of claim 6 , wherein the amount of radiation given is between about 1 gy to about 30 gy.

8. The method of claim 5 wherein the mammalian subject is suffering from human papilloma virus associated cancer.

9. The method of claim 5 wherein the mammalian subject is suffering from colon adenocarcinoma.

10. The method of claim 1 , wherein the albumin protein is human.

11. The method of claim 1 , wherein the Flt3L protein is human.

12. The method of claim 1 wherein the polypeptide comprises a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1.

13. The method of claim 1 wherein the polypeptide comprises a sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 1.

14. The method of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

15. The method of claim 1 wherein the mammalian subject is suffering from human papilloma virus associated cancer.

16. The method of claim 1 wherein the mammalian subject is suffering from colon adenocarcinoma.

17. A method of treating cancer in a mammalian subject in need thereof, comprising: administering to the mammalian subject an effective amount of a composition comprising a polypeptide comprising albumin protein linked to a FMS-like tyrosine kinase 3 ligand (Flt3L) protein, to thereby treat the cancer in the mammalian subject, and wherein the albumin protein is murine.

18. The method of claim 17 wherein the Flt3L protein is murine.

19. The method of claim 17 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

20. The method of claim 17 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

Assignees

• Univ Johns Hopkins

Inventors

• Wu T C
• Hung Chien-Fu
• Lam Brandon

Classifications

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61K38/19

  Cytokines; Lymphokines; Interferons · CPC title

• A61K38/38

  Albumins · CPC title

• C07K14/475

  Growth factors; Growth regulators · CPC title